At a glance
What is current practice and why address it?
In June 2020, the Organ Procurement and Transplantation Network (OPTN) Board of Directors approved a policy creating a National Heart Review Board (NHRB) for pediatric candidates. It was created to make sure pediatric heart exception requests are reviewed by those with pediatric heart expertise and to better inform decisions. The Heart Committee created a guidance document to provide more information on what reviewers should consider when making decisions on exception requests.
Guidance Addressing the Use of Pediatric Heart Exceptions
Dr. Shelley Hall, Chair of the OPTN Heart Transplantation Committee, reviews the Guidance Addressing the Use of Pediatric Heart Exceptions.
Terms you need to know
- Exception Request: When a candidate does not meet the requirements for a particular status, but their transplant program believes they are at a similar risk of death while waiting for transplant and have a similar potential for benefit after receiving a transplant, they may ask that the candidate be placed at that higher status. These requests are reviewed retrospectively by the review board.
- National Heart Review Board for Pediatrics: Board in charge of reviewing exception requests for pediatric heart candidates. Nine pediatric heart specialists from across the country review and make decisions on whether to approve or deny a request.
What’s the guidance?
- Provides information to better inform NHRB members’ decisions on pediatric heart exception requests
- Guidance is provided on the following pediatric heart diagnoses
- Dilated cardiomyopathy
- Hypertrophic or restrictive cardiomyopathy
- Single ventricle heart disease
- Coronary allograft vasculopathy and retransplant
What’s the anticipated impact of this document?
- What it’s expected to do
- Create more consistency in NHRB exception request decisions
- Help transplant programs better determine whether to submit an exception request
- Help transplant programs provide more important information in their exception requests
- Maintain flexibility for NHRB reviews of unique cases
- What it won’t do
- Will not change policy for exception requests
Themes to consider
- Usefulness of guidelines
- Ways to notify pediatric heart transplant community about guidelines
Status: Public Comment
Sponsoring Committee: Heart Transplantation Committee
Strategic Goal: Provide equity in access to transplants
David Rosenthal | 08/16/2020
Thank you for the opportunity to provide feedback on this document. It is a timely and important project that I support strongly. However, there are specific areas in which I believe this work could be improved, both for clarity and content. 1. Explanatory notes p 6 last paragraph suggest that purpose of the guidance is for under 5kg and 10 kg is to prevent situations in which a candidate is given a VAD just to achieve a higher status for transplant. There is no evidence that this practice exists, or is a significant problem. The guidance is developed because some centers are not comfortable placing VADs in smaller patients and a balance is being struck between access to care for patients at such centers, and the overall donor supply. 2. Category 1. The formatting is ambiguous with respect to the sub criteria. It is stated that a candidate must meet all of the following criteria, but is not clear what is a criteria and what is a sub-criteria. The language and formatting should not be ambiguous on such a crucial matter. 3. For DCM less than 5 kg, line 42, page 13. Continuous infusion of milrinone at 0.5 mcg/kg-min is not a high dose inotropic infusion in current practice. It is virtually a required therapy for DCM in the pediatric ICU. For 1A, a higher bar should be set. The category of single high dose infusion should be eliminated as it does not reliably identify a group of patients equivalent to other 1A risk categories. 4. For DCM less than 10 kg, line 42, page 13, the same applies, but in addition, the results from VAD support in this group are sufficiently reliable that I would question the need for this criteria to remain in the document. 5. For older patients, line 44-51, page 13. The presence of arrhythmias is not generally regarded as a contra-indication to VAD support, and in fact, this condition most commonly improves with placement of MCS and should therefore not be considered a reason for 1A exception. 6. For Category 2, line 62, page 14, it would be useful to specify an approximate time frame for the realtionship between the episode of sudden death or the arrhythmia or syncopal events, in relation to the exception request. 7. For Category 3, line 69, page 14, would this criteria apply to all Fontan patients, irrespective of the patient age (so long as the patient was pediatric). In other words, would a 7 yo Fontan qualify, or is this meant to be limited to adolescent patients, in whom the comparison to adult listing status is more incongruous. With the exception of clarifying this point, I strongly support this exception listing status for this population, who generally do not respond as effectively to inotropic support as do DCM patients, and who also have inferior results with MCS as compared to DCM patients. 8. For Category 4, line 87, page 15. This population is urgently in need of higher listing status and I support the effort to define patients at particular risk. However, the criteria as listed are somewhat problematic. First, is it required that the patient be admitted to the transplant hospital? It does not appear in the exception guidance and should be clarified. Second, given the nature of coronary allograft vasculopathy, I doubt that anyone could reliably diagnose triple vessel disease, and further doubt its relevance to prognosis. Third, given that patients with this diagnosis may undergo catheterization after a period of medical optimization, including vigorous diuresis and perhaps inotropic support, I do not believe that the absence of “restrictive hemodynamics” on catheterization represents a population that is distinct from those patients identified as such. The criteria as written incentivize centers to measure hemodynamics under suboptimal conditions in order to qualify for an exception. Furthermore, such patients frequently have multiple catheterizations; is it legitimate to select the one that supports restrictive hemodynamics? As an example, a patient may present with fluid overload and have a catheterization that demonstrates restrictive physiology. Then aggressive diuretics are initiated and fluid limitations imposed. A repeat catheterization is performed to assess efficacy of this approach and shows normalized hemodynamics. What is the center intended to report? This could be improved by expanding the criteria to include diastolic heart failure with frequent admissions for therapy, without diluting the severity of the criteria. 9. In response to the feedback questions, I believe the criteria are nicely inclusive of the relevant contra-indications for VAD support, perhaps even a bit overly inclusive. I do not think they need to be further broadened. As concerns sensitization and CAV, there is insufficient consensus as to how to measure sensitization for this to be included in the 1A exception criteria, in my opinion.
Seth Hollander | 08/21/2020
I would like to echo all of the comments offered by Dr. Rosenthal. As a rotating member of exception request review committee, I strongly support guidance for pediatric programs seeking exceptions. However, the guidance much match best practices and not further promote inequity in the system. In particular, I would like to emphasize my disagreement with two points: 1) Supporting exceptions in children <10 kg who are not on VAD support. Our center routinely places VADs in children 5-10 kg, as do other high-risk implanting centers. Such an exception would disadvantage these patients and disincentivise centers from contenting this practice. Instead, centers who have a patient who would otherwise received advanced therapies at a more experienced center, should seek out transfer of the patient to that center so as not to disantangate them from both status 1A (on VAD) as well as the best treatment options available to them. 2) Milrinone of 0.5. As Dr. Rosenthal mentioned, milrinone of 0.5 is not "high dose" and is used standardly, even in "stable" patients who are feeding intolerant at our center. Moreover, the institution and dose of inotropes is often determined by the ICU not necessarily the transplant physician, who may disagree with that choice. Hence, milrinone 0.5 is too broad a brush to be used as a determinant of illness severity and/or instability equivalent to the need for VAD support. 3) Arrhythmia is rarely, if ever a contraindication to VAD support. In fact, it is often an indication to implant a VAD as arrhythmia often improves after implantation.
Region 4 | 08/26/2020
Region 4 vote: 5 Strongly Support, 10 Support, 8 Neutral/Abstain, 0 Oppose, 1 Strongly Oppose Region 4 supported the proposal. During the discussion, one attendee commented that there should be more details on what would be considered a VAD contraindication for patients in the 5-10 kg range and one attendee suggested the guidance be revised based on broader pediatric heart transplant consensus.
Anonymous | 08/26/2020
This proposal serves to address two important deficiencies in the current system. 1. It is nearly impossible to achieve any level of consistency across regions without some accepted guidelines to help frame the exception requests and adjudication. 2. Under the current system, the majority of reviewers for any pediatric exceptions request are adult providers. In this context, I fully support the effort but would add the following comments. In response to a prior comment, I believe the proposed 1A exception guidelines regarding children with dilated cardiomyopathy who are 5-10 kg at the time of listing are reasonable. While it is true, some of these children may be VAD eligible, independent of center volume, it is reasonable to request 1A exception under the conditions as proposed. Further, these children are at similar risk and may derive similar benefit as many conventional 1A children with congenital heart disease on milrinone for example. I would however, be a bit more restrictive for this group, and remove "feeding intolerance" from the criteria satisfying the evidence of poor systemic perfusion. The other point I would like to address are the recommendations around children with documented coronary allograft vasculopathy (CAV). The use of revascularization for pediatric CAV has not been shown to significantly alter the natural history of this typically progressive disease. I would propose that a child with CAV of any grade AND graft dysfunction (based on Ejection fraction, PCWP, dysrhythmias perhaps?) as well as any child with CAV2 or higher should be granted a status 1B exception. These children have a real risk of sudden death and would often not be well served as status 2 candidates.
Peter Eckman | 08/27/2020
As an adult transplant cardiologist, I do not believe I am best qualified to comment on pediatric heart transplant exception requests. This patient population is incredibly different from adult candidates, and is asking adult specialists to comment on these candidates is inappropriate. It is clearly in the best interests of pediatric candidates to be evaluated by pediatric heart transplant specialists. I can't imagine a compelling reason to continue the present approach of using unqualified adult heart transplant specialists to perform this essential review task.
Region 5 | 08/28/2020
Region 5 vote: 3 Strongly Support, 20 Support, 10 Neutral/Abstain, 0 Oppose, 0 Strongly Oppose. Region 5 supported the proposal and had the following comments: • The pediatric guidance allows for 1A status for pts on milrinone alone if under 10 kg, we don’t support this and it is contrary to the last revision to listing status • We strongly support the guidance document that has been developed. • We want to thank the committee for their work on this. This guidance addresses many of the gaps presented since the last policy changes for pediatric heart allocation and will certainly be a positive change for families.
Region 7 | 09/10/2020
Region 7 vote: 5 Strongly Support, 8 Support, 4 Neutral/Abstain, 0 Oppose, 0 Strongly Oppose Region 7 supported the proposal and had the following comments: • Attendee stated that these are important changes, and are in support. However, they added that they would like the committee to fully investigate the root causes behind the exception requests, to properly account for those causes as we move toward Continuous Distribution. • An attendee added that they have been advocating for this and believe it is unsafe and unfair to have adult Cardiologists making decisions on behalf of pediatric candidates. This change is overdue and very appropriate. • An attendee asked if they would consider a PRA cutoff like they do in Canada. The Committee encouraged the region to submit more comments like these for the committee to consider.
Region 3 | 09/15/2020
Region 3 vote: 2 Strongly Support; 19 Support; 5 Neutral/Abstain; 1 Oppose, 0 Strongly Oppose: No comments during discussion Comments submitted online during meeting: • This would allow carte blanche status 1B for all Fontan patients • Agree with guidance and not change in policy • Monitor and if guidance does not work we should consider policy change
Ashwin Lal | 09/17/2020
Agree with most of the previous comments particularly from Dr. Rosenthal & Hollander and the move to have a pediatric review panel. 1) I too am concerned about DCM patients between 5-10 kg given 1A status. Experience has increased beyond the highest volume centers and a patient in this age weight range with systemic symptoms would benefit from a VAD. 2) I don't have the same objection to Milrinone therapy threshold. I agree that .5 is not truly high dose but identifies patients who are inotrope dependent. Having this threshold would hopefully avoid the circumstance where someone was deemed inotrope dependent even if they are on a "homeopathic" dose (as a reviewer I have seen adult patients on 2 inotropes where the second inotrope was simply to increase their status). The wording/intent could be clarified. 3) I had a similar question about whether CAV patients need to be admitted to qualify for 1A status. 4) The issue of sensitization is an important one, but agree that there may be too much variability in assessment to put this in writing
Region 8 | 09/22/2020
Region 8 vote: 5 strongly support, 10 support, 6 neutral/abstain, 0 oppose, 0 strongly oppose No comments
American Society of Transplantation | 09/24/2020
The American Society of Transplantation supports this proposal that aims to provide greater clarity and guidance for the status of pediatric candidates for heart transplantation with the following diagnoses: dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, cardiac allograft vasculopathy. The proposal makes reasonable recommendations regarding the process to upgrade different types of cardiomyopathy in the pediatric population. Overall, for the majority of types it creates greater alignment with the adult policy. Additional clarity regarding contraindications for mechanical circulatory support would be beneficial in dilated cardiomyopathy candidates. We offer the following points that we believe warrant additional attention before moving this proposal forward for final approval: • Dilated Cardiomyopathy: o Guidance is stratified by weight and inotrope utilization (similar to the adult policy with the absence of specific hemodynamic requirements) o Guidance is also provided for contraindications for mechanical circulatory support. These criteria are somewhat vague – but this does allow for center-specific differences. • Hypertrophic/Restrictive Cardiomyopathy o The proposal suggests this group is most adversely impacted by the current status system. The guidance in this proposal provides a clearer path to upgrade to 1A status and similar to the adult policy. • Single Ventricle Heart Disease o The guidance provides aligns the pediatric policy with the adult policy. • Coronary Allograft Vasculopathy & Re-transplantation o The proposal provides reasonable criteria to guide upgrade to status 1A. • Supporting exceptions in children <10 kg who are not on VAD support. Some of our members disagree with this exception. Their concern is that smaller centers may not be comfortable placing VADs in small children, and this would give children in these centers an advantage over children at larger, more skilled centers. We also feel that this exception could potentially disincentivize centers from placing a VAD and lead to suboptimal outcomes. • Milrinone of 0.5mcg/kg/minutes should not be considered "high dose”. Many centers use this dose for children who are feeding intolerant to improve nutrition. We do not feel that this dose always represents severe illness. • We suggest that the committee consider specifying what the VAD contraindications are for the 5-10kg group. To respond to the request for feedback, we do not think that there are other VAD contraindications that need to be considered at this time. • To respond to the request for feedback, there are not sufficient data to support the use of a stringent “measure of sensitization” for Status 1A listing for CAV candidates.
Anonymous | 09/24/2020
definitely needed as attempts to improve "fairness" to certain groups in allocation policies always seem to cause "unfairness" to other groups. most centers palliate/repair congenital defects and by the time transplant is needed, those pts. have complications/factors that may influence morbidity/survival/longevity. data does not reflect that yet...but given time, it will..... until then, exceptions will need to be implemented & the guide is an excellent start!
Region 1 | 09/24/2020
Region 1 vote: 4 Strongly Support, 3 Support, 5 Neutral/Abstain, 0 Oppose, 0 Strongly Oppose Comments: Region 1 supports this guidance and had no comments.
Region 2 | 09/25/2020
Region 2 vote: 8 Strongly Support, 15 Support, 9 Neutral/Abstain, 0 Oppose, 0 Strongly Oppose Comments: An attendee commented that some of the metrics for inotropic agents and their doses require adjustments to better align with current pediatric pharmacologic management for pediatric patients with end-stage heart disease. What does the committee consider low, medium, and high dosage for this population? They request that the committee spend more time fine-tuning the guidance document to establish more appropriate metrics.